High-throughput DNA methylation analysis in colorectal cancer and childhood leukemia

Abstract

The first study described the colon tumor-specific methylation of a low CG-dense CpG island that is located in the first intron of the PTPRG gene (PTPRGint1). High levels of specificity and sensitivity of this region were observed in sporadic and familial colon cancer which makes this region interesting for application in epigenetic screening panels. In the second study the relation between mutations and DNA methylation was investigated in an attempt to identify initiating factors for DNA methylation in colon cancer. In this study, we were unable to identify an intrinsic tendency towards CpG island hypermethylation other than aberrant accumulation of CpG island methylation via a somatic mutation of BRAF. The relationship between BRAF mutations and DNA methylation was explored further in Chapter 4, which describes an improved study of DNA methylation in BRAF mutationassociated colon cancer. We describe BRAF mutation-specific promoter methylation of the FOX transcription factor genes FOXB1, FOXB2 and FOXD3 and speculate that this methylation might help these tumors escape BRAF-induced senescence. In the final study the DMH technique was combined with oligonucleotide microarrays that contained high CpG island coverage to determine the methylation patterns of infant B-ALL patients. The majority of MLL-rearranged infant ALL cases (i.e., those who are characterized by a t(4;11) or t(11;19) translocation) represent hypermethylated leukemias. In contrast, infant ALL patients with a t(9;11) translocation and those without any MLL translocation (wild-type MLL) displayed DNA methylation patterns that closely resembled the pattern seen in normal bone marrow. This study indicates that patients with a t(4;11) or t(11;19) translocation who have high levels of DNA methylation might be promising candidates for therapies that inhibit DNA methylation.